ViaDerma Inc (VDRM)

[Mistral]

ViaDerma pays Phillips Company for a non-exclusive right to manufacture and distribute (label) Viabecline, which is a clone of a five-year old product named Diabecline.

ViaDerma's "products" are based on the Phillips/Keough patent-pending transdermal delivery system referenced in my stickie. They have no innovative transdermal system under their name(s).

The Annual Report should clearly convey the above information.

This upcoming approval is only a bonus on the fact that we have Viabecline hitting market very soon, "a rollout of its FDA registered drug, Viabecline topical antibiotic" "The Company expects sales for 2017 to be about 500,000 units" at $125 per 5ml bottle, with a wholesale price to be established for the Clinics & Wound Care Centers."
We also have Onychomycosis which "Onychomycosis Clinical Studies Show Significant Results" and other products coming! This company will be worth over $1 in a short time. We have products that rival OWCP and CNBX which all started the same way at or below .01.
"Patent Pending use of its innovative transdermal system for the delivery of (CBD's) Calanoids and (THC) Tetrahydrocannabinol for the treatment of several diseases. The transdermal system can deliver through topical skin absorption to localized areas and directly into the blood stream."